PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy.

MLA

Jiang, Weixing, et al. “PD-L1 and VEGFR-2 Expression in Synchronous Metastatic Renal Cell Carcinoma Treated with Targeted Therapy Following Cytoreductive Nephrectomy.” Urologic Oncology, vol. 39, no. 1, Jan. 2021, p. 78.e9-78.e16. EBSCOhost, https://doi.org/10.1016/j.urolonc.2020.09.012.

APA

Jiang, W., Wang, D., Liu, X., Zheng, W., Wen, L., Shi, H., Zhang, H., Zhou, A., Li, C., Ma, J., Zheng, S., & Shou, J. (2021). PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy. Urologic Oncology, 39(1), 78.e9-78.e16. https://doi.org/10.1016/j.urolonc.2020.09.012

Chicago

Jiang, Weixing, Dong Wang, Xiaoqi Liu, Wei Zheng, Li Wen, Hongzhe Shi, Huijuan Zhang, et al. 2021. “PD-L1 and VEGFR-2 Expression in Synchronous Metastatic Renal Cell Carcinoma Treated with Targeted Therapy Following Cytoreductive Nephrectomy.” Urologic Oncology 39 (1): 78.e9-78.e16. doi:10.1016/j.urolonc.2020.09.012.